Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Arq. bras. med. vet. zootec. (Online) ; 72(5): 1639-1645, Sept.-Oct. 2020. tab
Artículo en Portugués | LILACS, VETINDEX | ID: biblio-1131532

RESUMEN

Objetivou-se avaliar os efeitos fisiológicos e sobre o consumo do propofol, relativos à anestesia epidural com levobupivacaína isolada ou associada a diferentes doses de tramadol. Para tal, 18 cadelas foram pré-tratadas com acepromazina, utilizando-se propofol para indução e manutenção anestésicas. Conforme o protocolo epidural instituído, formaram-se três grupos (n=6) tratados com levobupivacaína isolada (1,5mg/kg) (GL) ou acrescida de 2mg/kg (GLT2) ou 4mg/kg (GLT4) de tramadol, respectivamente. As fêmeas foram submetidas à mastectomia e à ovário-histerectomia (OH), registrando-se as variáveis fisiológicas nos períodos pré (TB e T0) e transanestésicos (T10 a T70), bem como a taxa mínima de propofol necessária. Houve redução da FC para o GL e o GLT4 em relação ao GLT2 (T30 a T70), detectando-se, no GL, redução da PAS e da PAD em relação ao TB. Maiores taxas de infusão do propofol foram necessárias para o GL (0,70±0,12mg/kg/min) em relação ao GLT2 (0,50±0,19mg/kg/min) e ao GLT4 (0,50±0,19mg/kg/min). Conclui-se que o tramadol potencializou o propofol, ao ofertar analgesia, independentemente da dose administrada. Todos os protocolos testados foram seguros e eficazes em cadelas submetidas à mastectomia e à OH.(AU)


The aim of this study was to evaluate the physiological and on propofol-sparing effects related to epidural anesthesia with levobupivacaine alone or combined with different doses of tramadol. For this purpose, 18 female dogs were pretreated with acepromazine, using propofol for induction and maintenance of anesthesia. Based on a previously established epidural (L7-S1) protocol, three groups (n=6) were treated with either levobupivacaine alone (1.5mg.k-1) (GL) or in association with to 2mg.kg-1 (GLT2) or 4mg.kg-1 (GLT4) of tramadol, respectively. These dogs were all undergoing mastectomy and ovariohysterectomy (OH). The physiological data were registered in the pre (TB and T0) and trans-anesthetic periods (T10 - T70), as well as the consumption of propofol. There was a reduction in the HR for GL and GLT4 in relation to GLT2 (T30 - T70) and reductions in SAP and DAP in relation to TB in the GL group. Higher continuous infusion rate of propofol were required for GL (0.70±0.12mg.kg-1.min-1) relative to GLT2 (0.50±0.19mg.kg-1.min-1) and GLT4 (0.50±0.19mg.kg-1.min-1). It was concluded that tramadol potentiated propofol, offering analgesia independently of its administered dose. All protocols tested were safe and effective in female dogs undergoing mastectomy and OH.(AU)


Asunto(s)
Animales , Femenino , Perros , Tramadol/análisis , Propofol/análisis , Levobupivacaína/análisis , Ovariectomía/veterinaria , Anestesia Local/veterinaria , Mastectomía/veterinaria
2.
Rev Port Cardiol ; 19(5): 581-5, 2000 May.
Artículo en Portugués | MEDLINE | ID: mdl-10916431

RESUMEN

INTRODUCTION AND AIMS: Homocysteinemia is an independent risk factor of coronary artery disease and of myocardial infarction. In the present study we intend to relate fasting homocystein levels to prognosis after a myocardial infarction. METHODS: From 1990 to 1992, we studied fasting homocysteinemia levels on a group of 112 patients aged under 56 years that had suffered a myocardial infarction between 3 and 12 months before. We obtained, the patients names, addresses, phone numbers and physicians' name. Seven years later (on average) we collected data regarding the patients evolution, consulting medical records, their physicians or by personal contact. We evaluated complications, namely mortality, vascular morbidity, such as unstable angina, re-infarction, stroke, and the need for invasive procedures (catheterism, PTCA, CABG). According to previous studies of the group, we used a cut-point of 10.10 mumol/L to define patients with normal or pathological levels of homocysteinemia. We excluded all patients that took vitamin B supplements, co-factors of HC metabolism, during this follow-up. RESULTS: We were able to obtain data on 110 patients. Patients with normal HC levels (n = 62) presented less global complications (26 versus 72%, p < 0.0001), non significant tendency to have lower mortality (1.6 versus 6%), had lower morbidity (14 versus 36%, p < 0.01) and lower invasive procedure need (18 versus 48%, p < 0.001). In the group with pathological homocystein levels (n = 48), those with higher homocystein levels presented a higher degree of complications. CONCLUSIONS: In this population with myocardial infarction under 56 years of age, a high homocysteinemia level is an important prognostic factor. This study suggests that we can improve the prognosis and decrease the complications after myocardial infarction by lowering elevated homocystein levels.


Asunto(s)
Homocisteína/sangre , Infarto del Miocardio/sangre , Infarto del Miocardio/mortalidad , Humanos , Persona de Mediana Edad , Pronóstico
3.
Rev Port Cardiol ; 19(4): 471-4, 2000 Apr.
Artículo en Portugués | MEDLINE | ID: mdl-10874843

RESUMEN

INTRODUCTION AND AIMS: Homocysteinemia (HC) and smoking are both important risk factors for vascular disease. In the present study, we intend to evaluate the influence of smoking habits on HC values as well as on vitamins B6, B12 and folic acid, co-factors of HC metabolism. METHODS: We measured fasting homocysteinemia (basal) and homocysteinemia 6 hours after an overload with 0.1 g methionine/kg body weight in 279 subjects. We also performed the dosage of plasma levels of B6 and B12 vitamins and of red cells folates. Smoking habits were inquired and the subjects were classified as non-smokers, current smokers or ex-smokers (if they had stopped smoking more than 1 month before the study). According to the smoking status, smokers were classified in three groups: less than 20 cigarettes a day, between 20 and 39 and 40 or more cigarettes a day. We studied basal and after methionine load homocysteinemia, B6, B12 and folic acid levels in each group. RESULTS: Smokers presented significantly higher levels of basal and after methionine load homocysteinemia then non-smokers (10.6 +/- 4.9 vs 9.4 +/- 2.6, and 26.8 +/- 10.0 vs 24.3 +/- 7.4 mumol/L, respectively, p < 0.05 for both and B6 levels (29.2 +/- 12.0 versus 32.6 +/- 12.0 mumol/L, p < 0.05). B12 and folic levels were similar in the two groups. These results were quite similar either in the normal subjects or in the subjects with a history of a cardiovascular event. The subjects who smoked 40 or more cigarettes per day, compared with those who smoked less then 20 cigarettes per day, presented higher levels of basal homocysteinemia (12.4 +/- 2.9 vs 10.0 +/- 5.5 mumol/L, p < 0.05) and lower levels of B6 (24.7 +/- 8.1 vs 31.7 +/- 12.6 mumol/L, p < 0.05). CONCLUSIONS: Smoking habits are related with the increase of basal and after methionine load homocysteinemia, probably because of a decrease in B6 vitamin levels. There is a proportional effect between the number of cigarettes smoked, B6 depletion and basal homocysteinemia increase. This study suggests that B6 vitamin supplements for smokers could decrease the vascular risk related with smoking habits.


Asunto(s)
Homocisteína/sangre , Metionina , Fumar , Adulto , Enfermedades Cardiovasculares/etiología , Femenino , Humanos , Masculino , Piridoxina/sangre , Factores de Riesgo
4.
Klin Wochenschr ; 69(9): 392-6, 1991 Jun 18.
Artículo en Alemán | MEDLINE | ID: mdl-1921241

RESUMEN

Infection is a major cause of morbidity and mortality in patients undergoing hemodialysis for end stage renal disease. Low plasma zinc levels have been associated with immunodepression in these patients. In a randomized, placebo controlled double-blind cross over study, plasma zinc levels, delayed hypersensivity to 7 Antigens (Merieux-Multitest), absolute lymphocyte counts, T- and B-lymphocytes, suppressor-T and helper T-cells and natural killer cells were studied in 25 hemodialysis patients before, during and after intravenous zinc supplementation for 8 weeks. The hemodialysis patients had significantly lower predialysis plasma zinc concentrations compared to 76 healthy controls (74 +/- 12 vs. 126 +/- 28 mcg/dl, p less than 0.001). The plasma zinc concentrations increased to the normal range during the treatment period. Lymphocyte subtype analysis showed a significant decrease of suppressor-T cells and an increase of the helper-T/suppressor-T ratio (2.09 +/- 0.26 vs. 3.18 +/- 0.48, p less than 0.05) after zinc supplementation. Delayed hypersensivity to intradermal antigens increased significantly only after zinc treatment (2.0 +/- 0.7 vs. 5.8 +/- 1.7, p less than 0.05), not after placebo. The changes were reversible after finishing the zinc treatment. It is concluded, that plasma zinc levels are reduced in hemodialysis patients and that the substitution of zinc restores some of the depressed immune functions in these patients.


Asunto(s)
Fallo Renal Crónico/inmunología , Subgrupos Linfocitarios/efectos de los fármacos , Diálisis Renal , Zinc/administración & dosificación , Relación CD4-CD8/efectos de los fármacos , Método Doble Ciego , Femenino , Estudios de Seguimiento , Humanos , Fallo Renal Crónico/terapia , Recuento de Leucocitos/efectos de los fármacos , Subgrupos Linfocitarios/inmunología , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Zinc/deficiencia
5.
J Clin Oncol ; 9(5): 827-31, 1991 May.
Artículo en Inglés | MEDLINE | ID: mdl-2016625

RESUMEN

In a prospective phase III multicenter trial, 213 patients with advanced measurable or nonmeasurable gastric cancer were randomized to receive methotrexate (MTX), fluorouracil (5-FU), and Adriamycin (doxorubicin; Farmitalia Carlo Erba, Milan, Italy) (FAMTX) or 5-FU, Adriamycin, and mitomycin (FAM). The results show a significantly superior response rate (41% v 9% [P less than .0001]), and survival (median, 42 weeks v 29 weeks [P = .004]) for FAMTX. There was a cumulative thrombocytopenia in FAM and not in FAMTX. The FAMTX protocol should be the reference treatment in future clinical trials that seek to improve the therapeutic outcome in advanced gastric cancer.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias Gástricas/tratamiento farmacológico , Adulto , Anciano , Doxorrubicina/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Masculino , Metotrexato/administración & dosificación , Persona de Mediana Edad , Estadificación de Neoplasias , Estudios Prospectivos , Inducción de Remisión , Neoplasias Gástricas/mortalidad , Neoplasias Gástricas/patología , Análisis de Supervivencia
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA